The more recent immunotherapy trials have, therefore, used additional inclusion and exclusion criteria to improve diagnostic accuracy, including positive detection of Aβ or tau pathology consistent with AD using PET neuroimaging. The gene discussed is MAPT; the disease is Alzheimer disease.